Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neuroblastoma 3Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Motor Activity 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Dendritic Cell Sarcoma, Interdigitating 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1

Interventions

pembrolizumab 155Gemcitabine 139Capecitabine 121Paclitaxel 118Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 92Cisplatin 89Irinotecan 87Carboplatin 84Radiosurgery 83Cyclophosphamide 70Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × beta-Glucans × Clear all
NCT04710290 2021-01-25

A Cohort Study of Beta-Glucan or Beta-Glucan Compound in Metastatic Cancers

E-DA Hospital

Phase 2/3 Unknown
90 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡